Genzyme’s Asian Expertise Drives Alnylan Co-Development Pact For TTR Candidates
This article was originally published in PharmAsia News
Executive Summary
RNAi pioneer Alnylan is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.